Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the ...

Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, and the expertise of a ...

CAMBRIDGE, Mass., May 1, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the first quarter ended March 31, 2025 ...

Blueprint Medicines (NASDAQ:BPMC) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release. Analysts are ...

Blueprint Medicines Corporation (NASDAQ:BPMC), a commercial-stage biotech firm with a market capitalization of $5.8 billion specializing in precision therapies for rare diseases, has been making ...

Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress Provided by PR Newswire Feb 28, 2025 5:00am ...

Blueprint Medicines Corporation (Nasdaq: BPMC) today provided a 2025 corporate outlook and strategy for continued growth leveraging the company's proven R&D and commercial capabilities.

During the last three months, 17 analysts shared their evaluations of Blueprint Medicines (NASDAQ:BPMC), revealing diverse outlooks from bullish to bearish. Summarizing their recent assessments ...

Blueprint Medicines' Q3 2023 earnings showed a 90% YoY increase in product sales driven by Ayvakit, but total revenue dipped. Read more here.

Blueprint Medicines delivered an exceptional quarter with a positive reception for Ayvakit in its first full-quarter post-launch. More than 800 patients were using the ISM treatment at the end of ...

Blueprint Medicines reports Q2 2023 revenue of $57.6M, driven by strong sales of Ayvakit. Analysts give the company an outperform rating.

Last Sunday, lots of people were gushing about Blueprint Medicines' experimental cancer drug. So why has the company's share price dropped 20%? The answer: biotech fund managers are paying ...